199 related articles for article (PubMed ID: 9635606)
1. Oral ganciclovir usage for cytomegalovirus prophylaxis in organ transplant recipients: is emergence of resistance imminent?
Singh N; Yu VL
Dig Dis Sci; 1998 Jun; 43(6):1190-2. PubMed ID: 9635606
[No Abstract] [Full Text] [Related]
2. Emergence of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient.
Bienvenu B; Thervet E; Bedrossian J; Scieux C; Mazeron MC; Thouvenot D; Legendre C
Transplant Proc; 2000 Mar; 32(2):407. PubMed ID: 10715457
[No Abstract] [Full Text] [Related]
3. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
[TBL] [Abstract][Full Text] [Related]
4. Ganciclovir prophylaxis for CMV disease infrequently associated with viral resistance.
AIDS Patient Care; 1995 Dec; 9(6):308. PubMed ID: 11361450
[No Abstract] [Full Text] [Related]
5. Ganciclovir susceptibilities of cytomegalovirus (CMV) isolates from solid organ transplant recipients with CMV viremia after antiviral prophylaxis.
Boivin G; Erice A; Crane DD; Dunn DL; Balfour HH
J Infect Dis; 1993 Aug; 168(2):332-5. PubMed ID: 8393055
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
Boivin G; Goyette N; Gilbert C; Humar A; Covington E
Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
[TBL] [Abstract][Full Text] [Related]
7. Lack of emergence of cytomegalovirus UL97 mutations conferring ganciclovir (GCV) resistance following preemptive GCV therapy in allogeneic stem cell transplant recipients.
Gilbert C; Roy J; Belanger R; Delage R; Beliveau C; Demers C; Boivin G
Antimicrob Agents Chemother; 2001 Dec; 45(12):3669-71. PubMed ID: 11709367
[TBL] [Abstract][Full Text] [Related]
8. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants.
Limaye AP; Corey L; Koelle DM; Davis CL; Boeckh M
Lancet; 2000 Aug; 356(9230):645-9. PubMed ID: 10968438
[TBL] [Abstract][Full Text] [Related]
9. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
Meylan PR; Pascual M
Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
[No Abstract] [Full Text] [Related]
10. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir.
Boivin G; Goyette N; Rollag H; Jardine AG; Pescovitz MD; Asberg A; Ives J; Hartmann A; Humar A
Antivir Ther; 2009; 14(5):697-704. PubMed ID: 19704173
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
12. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.
Hodson EM; Jones CA; Webster AC; Strippoli GF; Barclay PG; Kable K; Vimalachandra D; Craig JC
Lancet; 2005 Jun 18-24; 365(9477):2105-15. PubMed ID: 15964447
[TBL] [Abstract][Full Text] [Related]
13. Ganciclovir-resistant cytomegalovirus.
Legendre C
Lancet; 2000 Oct; 356(9238):1356. PubMed ID: 11073050
[No Abstract] [Full Text] [Related]
14. Drug resistance in cytomegalovirus: current knowledge and implications for patient management.
J Acquir Immune Defic Syndr Hum Retrovirol; 1996; 12 Suppl 1():S1-22. PubMed ID: 8680897
[No Abstract] [Full Text] [Related]
15. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
[TBL] [Abstract][Full Text] [Related]
16. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
Razonable RR; Rivero A; Rodriguez A; Wilson J; Daniels J; Jenkins G; Larson T; Hellinger WC; Spivey JR; Paya CV
J Infect Dis; 2001 Dec; 184(11):1461-4. PubMed ID: 11709790
[TBL] [Abstract][Full Text] [Related]
17. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
[TBL] [Abstract][Full Text] [Related]
18. Ganciclovir-resistant cytomegalovirus in organ transplant recipients.
Limaye AP
Clin Infect Dis; 2002 Oct; 35(7):866-72. PubMed ID: 12228824
[TBL] [Abstract][Full Text] [Related]
19. New prophylactic treatment strategy for cytomegalovirus disease.
Lake KD
Am J Health Syst Pharm; 2003 Dec; 60(23 Suppl 8):S13-6. PubMed ID: 14686230
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir.
Razonable RR; van Cruijsen H; Brown RA; Wilson JA; Harmsen WS; Wiesner RH; Smith TF; Paya CV
J Infect Dis; 2003 Jun; 187(11):1801-8. PubMed ID: 12751039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]